Cargando…
BET inhibitors potentiate melanoma ferroptosis and immunotherapy through AKR1C2 inhibition
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694977/ https://www.ncbi.nlm.nih.gov/pubmed/38049916 http://dx.doi.org/10.1186/s40779-023-00497-1 |
| _version_ | 1785153493788524544 |
|---|---|
| author | Meng, Yu Sun, Hui-Yan He, Yi Zhou, Qian Liu, Yi-Huang Su, Hui Yin, Ming-Zhu Zeng, Fu-Rong Chen, Xiang Deng, Guang-Tong |
| author_facet | Meng, Yu Sun, Hui-Yan He, Yi Zhou, Qian Liu, Yi-Huang Su, Hui Yin, Ming-Zhu Zeng, Fu-Rong Chen, Xiang Deng, Guang-Tong |
| author_sort | Meng, Yu |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10694977 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-106949772023-12-05 BET inhibitors potentiate melanoma ferroptosis and immunotherapy through AKR1C2 inhibition Meng, Yu Sun, Hui-Yan He, Yi Zhou, Qian Liu, Yi-Huang Su, Hui Yin, Ming-Zhu Zeng, Fu-Rong Chen, Xiang Deng, Guang-Tong Mil Med Res Letter to the Editor BioMed Central 2023-12-04 /pmc/articles/PMC10694977/ /pubmed/38049916 http://dx.doi.org/10.1186/s40779-023-00497-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Letter to the Editor Meng, Yu Sun, Hui-Yan He, Yi Zhou, Qian Liu, Yi-Huang Su, Hui Yin, Ming-Zhu Zeng, Fu-Rong Chen, Xiang Deng, Guang-Tong BET inhibitors potentiate melanoma ferroptosis and immunotherapy through AKR1C2 inhibition |
| title | BET inhibitors potentiate melanoma ferroptosis and immunotherapy through AKR1C2 inhibition |
| title_full | BET inhibitors potentiate melanoma ferroptosis and immunotherapy through AKR1C2 inhibition |
| title_fullStr | BET inhibitors potentiate melanoma ferroptosis and immunotherapy through AKR1C2 inhibition |
| title_full_unstemmed | BET inhibitors potentiate melanoma ferroptosis and immunotherapy through AKR1C2 inhibition |
| title_short | BET inhibitors potentiate melanoma ferroptosis and immunotherapy through AKR1C2 inhibition |
| title_sort | bet inhibitors potentiate melanoma ferroptosis and immunotherapy through akr1c2 inhibition |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694977/ https://www.ncbi.nlm.nih.gov/pubmed/38049916 http://dx.doi.org/10.1186/s40779-023-00497-1 |
| work_keys_str_mv | AT mengyu betinhibitorspotentiatemelanomaferroptosisandimmunotherapythroughakr1c2inhibition AT sunhuiyan betinhibitorspotentiatemelanomaferroptosisandimmunotherapythroughakr1c2inhibition AT heyi betinhibitorspotentiatemelanomaferroptosisandimmunotherapythroughakr1c2inhibition AT zhouqian betinhibitorspotentiatemelanomaferroptosisandimmunotherapythroughakr1c2inhibition AT liuyihuang betinhibitorspotentiatemelanomaferroptosisandimmunotherapythroughakr1c2inhibition AT suhui betinhibitorspotentiatemelanomaferroptosisandimmunotherapythroughakr1c2inhibition AT yinmingzhu betinhibitorspotentiatemelanomaferroptosisandimmunotherapythroughakr1c2inhibition AT zengfurong betinhibitorspotentiatemelanomaferroptosisandimmunotherapythroughakr1c2inhibition AT chenxiang betinhibitorspotentiatemelanomaferroptosisandimmunotherapythroughakr1c2inhibition AT dengguangtong betinhibitorspotentiatemelanomaferroptosisandimmunotherapythroughakr1c2inhibition |